Key takeaways
- Beiersdorf reported third-quarter 2026 revenue of 2.36 billion euros on 27 October, down 1.3 percent organically.
- Nivea, the flagship brand, fell 4.9 percent organically, while the Derma business grew 10.6 percent.
- The company kept its 2026 guidance for a low-single-digit organic sales decline and an EBIT margin of at least 11.8 percent.
Beiersdorf Nivea sales fell again in the third quarter of 2026. Group revenue reached 2.36 billion euros, a 1.3 percent organic decline, and Nivea, the flagship brand, was down 4.9 percent on an organic basis.
The figures were published on Tuesday, 27 October. Revenue for the first nine months fell 2.8 percent on a comparable basis to 7.3 billion euros, and the company kept its 2026 outlook for a low-single-digit organic sales decline. Teleborsa reports that the shares fell about 4 percent in Frankfurt trading.
Third-Quarter Sales Across the Group
Consumer net sales reached 1.94 billion euros in the quarter, down 0.7 percent organically. The tesa business fell 4.3 percent organically to 422 million euros. BeautyMatter ties that drop to semiconductor shortages hitting tesa’s electronics business, and says its broader industry portfolio grew.
RetailDetail said sales declined again in the third quarter and put the group’s quarterly revenue at 2.36 billion euros.
The rounded figures differ slightly between reports. Teleborsa gives net sales of 2.4 billion euros and BeautyMatter gives 2.362 billion, but all three show the same 1.3 percent organic decline.
Key figures
Group revenue reached 2.36 billion euros in the third quarter, down 1.3 percent organically. Nivea sales fell 4.9 percent organically to 1.263 billion euros, while Derma grew 10.6 percent to 401 million euros. For 2026 the group still expects a low-single-digit organic decline and an EBIT margin of at least 11.8 percent, excluding special factors.
Nivea Falls 4.9 Percent
Nivea, including the Labello brand, generated 1.263 billion euros in the quarter, down 4.9 percent organically. Excluding Russia, the decline was 3.2 percent, BeautyMatter reports.
RetailDetail describes Nivea as a brand that continues to struggle, while noting early signs of recovery. BeautyMatter reports that Nivea’s global sell-out growth in the quarter was an early sign that its rebalancing measures were gaining traction, although sell-out growth still trails the market.
Teleborsa says the company attributes part of the drop to temporary factors, including trade tensions and inventory reduction, and expects these to ease gradually by the end of the year. BeautyMatter adds that retailer disputes also weighed on the quarter, and that Chief Executive Vincent Warnery did not name the retailers or the terms of the disputes.
On the second-quarter call, Warnery had attributed about 30 percent of the gap to retailer conflicts, BeautyMatter reports, saying retailers had wanted price deflation. In this quarter he said most of those disputes had been resolved, though some would continue to affect the fourth quarter.
A commercial dispute involving the Russian subsidiary and a local business partner also affected the quarter. BeautyMatter reports that Warnery said the dispute had been resolved. On the earnings call, an HSBC analyst asked about the gap between sell-in and sell-out, and Warnery pointed to the brand’s complexity with Russia as a strong factor in sell-in.
Warnery acknowledged that Nivea is not yet growing in line with the market, but said the brand gained market share in emerging markets over the last three months. He said it is still struggling in Europe because of customer conflicts that are almost over.
Derma, La Prairie and Healthcare
BeautyMatter says Nivea’s scale means its decline can outweigh growth across Beiersdorf’s smaller brands, and that Derma’s growth gives the group room to expand beyond its flagship.
Derma, which includes the Eucerin and Aquaphor brands, reached 401 million euros, up 10.6 percent organically. BeautyMatter reports that Aquaphor’s expansion into bodycare grew 13 percent organically in the quarter, and that Aquaphor Body reached the number three position in the US therapeutic skincare market within six weeks of its July launch. He added that Derma is growing across regions and categories, supported by expansion into new white spaces and the rollout of breakthrough innovations. BeautyMatter says the Eucerin DermoPure Clinical ProBiom8 line is based on Beiersdorf’s microbiome research and on expertise gained through its acquisition of S-Biomedic, a life-science company.
Warnery said Derma’s growth could partly be attributed to consumers’ appetite for efficacy, scientific credibility and dermatologist endorsements. He said the business “is not driven by only one market or innovation”. He also pointed to Eucerin DermoPure Clinical ProBiom8, a line for acne-prone skin that launched in September in select European markets.
The luxury brand La Prairie rose 8.5 percent to 117 million euros, according to BeautyMatter. It had fallen 14.9 percent organically in the first quarter after retail disruptions in US department stores and Chinese travel retail. Its net sales in China rose 28 percent in the quarter, Warnery said, and healthcare grew 5.7 percent.
Nivea, the flagship brand, was down 4.9 percent on an organic basis.
Nine-Month Revenue and the 2026 Outlook
Over the first nine months, revenue fell 2.8 percent on a comparable basis to 7.3 billion euros. The group’s outlook for 2026 is unchanged: a low-single-digit organic sales decline and an EBIT margin, excluding special factors, of at least 11.8 percent.
BeautyMatter gives the consumer business a separate target of at least 11.0 percent for the same margin measure. It also writes that the earnings call left open how much of Nivea’s decline will persist once the pressures ease, and whether the turnaround can restore market share.
What Comes Next for Nivea
Beiersdorf began rebalancing Nivea in the second half of 2025 and launched an 18-month turnaround plan for the brand in August 2026, according to BeautyMatter. The plan covers faster innovation, stronger accessibility and value-for-money offers, and greater use of Nivea’s local relevance.
Warnery said the fourth quarter would still be affected, but that he expects the effect to fade gradually, leaving healthy stock levels by the end of the year. He also said the company is getting closer to having the same level of sell-in and sell-out.